NASDAQ:ACIU AC Immune Q2 2026 Earnings Report $2.39 -0.21 (-8.08%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$2.49 +0.10 (+4.14%) As of 07/10/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast AC Immune EPS ResultsActual EPSN/AConsensus EPS $0.12Beat/MissN/AOne Year Ago EPSN/AAC Immune Revenue ResultsActual RevenueN/AExpected Revenue$34.05 millionBeat/MissN/AYoY Revenue GrowthN/AAC Immune Announcement DetailsQuarterQ2 2026Date8/4/2026TimeBefore Market OpensConference Call DateWednesday, August 5, 2026Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile AC Immune Earnings HeadlinesAC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC® 2026July 7, 2026 | globenewswire.comAnalysts Conflicted on These Healthcare Names: Sarepta Therapeutics (SRPT), Niagen Bioscience (NAGE) and AC Immune SA (ACIU)July 2, 2026 | theglobeandmail.comPorter flew 3,300 miles to investigate this systemPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.July 12 at 1:00 AM | Porter & Company (Ad)AC Immune: Holding Into A Make-Or-Break H2 2026 ReadoutJuly 2, 2026 | seekingalpha.comAC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s DiseaseJuly 1, 2026 | markets.businessinsider.comAC Immune Reports Interim 12-Month ABATE Data for ACI-24 in Prodromal Alzheimer’s DiseaseJune 30, 2026 | quiverquant.comQSee More AC Immune Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like AC Immune? Sign up for Earnings360's daily newsletter to receive timely earnings updates on AC Immune and other key companies, straight to your email. Email Address About AC ImmuneAC Immune (NASDAQ:ACIU) AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates. Since its founding in 2003, AC Immune has advanced multiple programs into clinical development. Its SupraAntigen™ platform is designed to generate active vaccines that elicit a targeted immune response against disease-associated proteins, while its Morphomer™ platform discovers small molecules that bind misfolded proteins and inhibit their toxic aggregation. Among the company’s leading assets are anti-tau vaccine candidates in mid-stage clinical trials and small-molecule inhibitors aimed at disrupting toxic oligomer formation. AC Immune maintains collaborations and strategic partnerships with major pharmaceutical firms to accelerate development and expand global reach. Notable alliances include research agreements with Janssen Pharmaceuticals and UCB to co-develop immunotherapies for Alzheimer’s and Parkinson’s diseases, as well as partnerships with Eli Lilly and Genentech focused on diagnostic imaging agents. These collaborations strengthen AC Immune’s ability to advance its pipeline while accessing broader regulatory and commercialization expertise. Under the leadership of CEO Dr. Andrea Pfeifer, who co-founded the company and has guided its growth since inception, AC Immune continues to invest in innovative approaches to neurodegeneration. The company’s integrated research and development model, combining both therapeutic and diagnostic strategies, aims to deliver precision solutions that address unmet medical needs in aging populations across North America, Europe and Asia. View AC Immune ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/06 - 07/10Delta Air Lines Lives Up to Its Claims: Shares Can Keep ClimbingWhy WD-40 Is Proving Great Businesses Never Go Out of StyleAeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion TargetStarbucks Builds Sovereign AI to Cut $400 Million in Software CostsPriceSmart Stock Eyes $220 as Chile Expansion Fuels GrowthPepsiCo’s Dividend Could Turn Patience Into Real Profit Upcoming Earnings Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)Cintas (7/15/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026)BlackRock (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
